Meeting
2011 ASCO Annual Meeting
Axitinib inhibition of [18F] fluorothymidine (FLT) uptake in patients (pts) with colorectal cancer (CRC): Implications for cytotoxic chemotherapy combinations.
Authors
C. Hoh
University of California, San Diego, La Jolla, CA
C. Hoh , J. R. Infante , H. A. Burris III, J. C. Tarazi , S. Kim , B. Rosbrook , T. R. Reid
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00460603
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3591)
Abstract #
3591
Poster Bd #
16G
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Pharmacodynamic (PD) assessment using FLT-PET/CT imaging in patients treated with an interrupted high-dose axitinib schedule.
First Author: Ludimila Cavalcante
Poster
2015 Gastrointestinal Cancers Symposium
Phase II Pharmacodynamic Trial of Palbociclib in Patients with KRAS Mutant Colorectal Cancer.
First Author: Mark H. O'Hara
Poster
2013 ASCO Annual Meeting
NCI 8609: Interim fluoro-3’-deoxythymidine (FLT) PET imaging findings from the phase I trial of PARP inhibitor veliparib (V) and carboplatin (C) in advanced breast cancer.
First Author: Bhuvaneswari Ramaswamy
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study.
First Author: Antoine Hollebecque